Clinical studies have demonstrated that immunisation with anti-sTn vaccines can induce production of sTn specific IgGs [76,77,78], and in murine models sTn vaccines have been found to induce antibody mediated tumour protection [44]. Here, EEF1A2 is linked to neoplasm.